Phase 2 Trial of Irofulven to Treat Metastatic Castration-Resistant Prostate Cancer Opens in Denmark

Phase 2 Trial of Irofulven to Treat Metastatic Castration-Resistant Prostate Cancer Opens in Denmark
Oncology Venture announced that patient enrollment has begun in a Phase 2 study evaluating irofulven as a possible treatment for metastatic castration-resistant prostate cancer (mCRPC). Specifically, the trial  (NCT03643107) is for patients who failed to respond to one or two prior androgen receptor-targeted therapies – including Zytiga (abiraterone acetate) and Xtandi (enzalutamide) – and to Taxotere (docetaxel) for their disease. "The initiation of this Phase 2 study in prostate cancer patients is an important milestone in the development of Irofulven. This has been long under way but is as relevant as ever," Peter Buhl Jensen, MD, CEO of Oncology Venture, said in a press release. Irofulven is a man-made product that derives from a natural fungus toxin. It works by causing chemical changes in DNA that cancer cells are unable to repair – because they often have deficiencies in their DNA repair machinery – stopping them from dividing. According to Venture, irofulven works similarly to PARP inhibitors now in clinical use, which also exploit the deficiencies in the DNA repair mechanism of cancer cells. To date, irofulven has been tested in more than 19 clinical trials, including a Phase 3 study (
Subscribe or to access all post and page content.